Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - The company provided a business update regarding its REYOBIQ clinical program and CNSide U.S. commercialization [2][3] Company Developments - The latest corporate presentation was filed with the SEC in an 8-K filing and is available on the company's website [3] - The conference call included participation from the CEO and CFO, indicating a focus on future performance and operational results [3] Communication and Transparency - The company emphasized the availability of its press release and corporate presentation on its website for investor access [2][3]

Summary of Plus Therapeutics Conference Call - January 22, 2026 Company Overview - **Company**: Plus Therapeutics (NasdaqCM:PSTV) - **Focus**: Development of CNSide and RIOVA clinical programs Key Points Financial Update - **Recent Offering**: Completed a $15 million oversubscribed financial offering on January 14, 2026, which extends the company's runway through 2027 [4] - **Use of Funds**: Funds will be used to expand CNSide investments to achieve break-even by 2027 and to complete ongoing phase II RIOVA clinical trials [4] RIOVA Clinical Program - **FDA Interaction**: Positive feedback from a Type B meeting with the FDA in November 2025, which will expedite RIOVA clinical development timelines [5] - **Trial Design**: Agreement on a randomized pivotal trial design focusing on neurologic condition improvements, patient-reported outcomes, and overall survival as key endpoints [6] - **2026 Goals**: Aim to identify optimal RIOVA dosing regimes and expand into a 12-patient dose expansion arm for additional safety and efficacy data [7] - **Enrollment Progress**: On track to complete phase II enrollment for recurrent glioblastoma (GBM) with data expected in Q4 2026 [7] CNSide Commercialization - **Licensure**: Achieved state licensure in 49 of 50 U.S. states, with agreements covering 67 million lives through partnerships with UnitedHealthcare and Humana [8] - **2026 Focus**: Targeting over 150 million covered lives through additional payer agreements, obtaining Medicare and Medicaid coverage, and ramping up testing utilization to reestablish previous commercial run rates of 1,250 tests per year [8] - **Physician Engagement**: Goal to establish a base of 50 unique ordering physicians, with a long-term target of reaching 200 [28] Operational Insights - **Testing Goals**: Aiming for 1,250 tests per year as a minimum goal, which is expected to cover only a quarter of the path to profitability; a target of 5,000 tests is needed for full profitability [31] - **Cost Efficiency**: Significant opportunities for automation and cost reductions have been identified since acquiring testing assets from the previous company [32] Strategic Outlook - **Market Positioning**: Emphasis on improving diagnostic capabilities with CNSide and bringing the RIOVA drug to market to address unmet medical needs in CNS cancers [35] - **Future Announcements**: Management is optimistic about upcoming announcements that could positively impact stock performance, with no immediate plans for a reverse stock split [19] Risk Factors - **Forward-Looking Statements**: The company has cautioned that actual results may differ from expectations due to various risks outlined in their SEC filings [3] Additional Considerations - **Payer Dynamics**: The company is working on obtaining PLA and DEX Z-Codes for Medicare and Medicaid coverage, which are crucial for expanding market access [26] - **Patient Demographics**: Noted that the demographic for CNSide testing skews younger, with a 60/40 split between private payers and Medicare [27] This summary encapsulates the critical updates and strategic direction of Plus Therapeutics as discussed in the conference call, highlighting both opportunities and challenges ahead.

Corporate Update January 2026 Power and precision in cancer radiotherapeutics NASDAQ: PSTV Cautionary Note Regarding Forward Looking Statements This presentation contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements m ...

Core Insights - Plus Therapeutics is focused on scaling up the commercialization of CNSide and preparing for pivotal trials of REYOBIQ in 2026 [2][6] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, developing targeted radiotherapeutics for challenging CNS cancers [10] - The company aims to enhance clinical outcomes through a combination of image-guided local beta radiation and targeted drug delivery [10] Clinical Programs - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed for CNS tumors, with potential advantages over existing therapies [6] - The REYOBIQ clinical program includes trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [6][8] - The ReSPECT-LM trial is expected to report data in Q3 2026, while the ReSPECT-GBM trial aims to complete enrollment and align with the FDA on pivotal trial design by Q4 2026 [7] Financial Updates - The company recently completed a $15 million offering to support its core business areas and extend its cash runway through 2027 [2] - Plus Therapeutics aims to cover 150 million US lives under various commercial payor agreements and achieve over 1,250 tests per year in commercial orders [7] CNSide Diagnostics - CNSide Diagnostics, a subsidiary of Plus Therapeutics, develops proprietary tests to identify tumor cells in the CNS, improving management for patients with leptomeningeal metastases [9]

Core Insights - Plus Therapeutics, Inc. is set to provide a business update on January 22, 2026, before market opening, followed by a conference call at 9:00 a.m. ET to discuss further details [1] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers, aiming to improve clinical outcomes [3] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery methods [3] - Plus Therapeutics has established a supply chain through strategic partnerships to facilitate the development, manufacturing, and potential commercialization of its products [3] Subsidiary Information - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary laboratory-developed tests, including CNSide®, which identifies tumor cells that have metastasized to the central nervous system in carcinoma and melanoma patients [4] - The CNSide® CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, enhancing the management of patients with leptomeningeal metastases [4]

Market Overview - U.S. markets ended the week with mixed results, as major benchmarks showed modest declines while small-cap stocks outperformed, with the Russell 2000 achieving record highs [2][4] - The Dow Jones Industrial Average and S&P 500 experienced slight decreases, while the Nasdaq also slipped, indicating an uneven market rally [2][3] Sector Performance - Semiconductor and AI-related technology stocks, particularly Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC), contributed to market stability earlier in the week, with TSMC reporting a 35% increase in net profit, driven by strong AI demand [3][6] - Bank earnings from Goldman Sachs and Morgan Stanley supported trading, despite rising Treasury yields and modest increases in oil prices [3] Small-Cap Stocks - The Russell 2000's performance marked a significant outperformance streak against the S&P 500, a trend not seen since 2008, bolstered by strong economic indicators such as low initial jobless claims [4] Notable Stock Movements - Venus Concept Inc. saw its stock surge over 500% after Madryn Asset Management acquired a 91% stake, leading to increased trading volume and investor interest despite recent revenue declines [8] - J.B. Hunt Transport Services Inc. reported mixed Q4 results, with revenue of approximately $3.097 billion slightly missing expectations, while earnings per share of $1.90 exceeded forecasts [11] - Plus Therapeutics Inc. faced a stock decline after pricing a public offering to raise $15 million at a discounted price, impacting investor sentiment [12] Analyst Insights - Rocket Lab USA, Inc. received a rare downgrade from Loop Capital, citing valuation concerns and near-term execution risks, which led to a decline in its stock price [10]

Group 1: Market Movements - Biotech and healthcare companies experienced notable movements in after-hours trading, with several small-cap firms showing strong gains due to corporate updates and investor momentum [1] Group 2: Company Updates - Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing a public offering priced at $0.38 per unit, aiming to raise approximately $15 million to support its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers [2] - Connect Biopharma Holdings Limited (CNTB) gained 5.96% to $2.31, recently highlighting new mechanism of action data for its lead candidate and outlining strategic priorities for 2026 [3] - ABVC BioPharma, Inc. (ABVC) added 3.37% to finish at $2.15, with the increase attributed to broader sector momentum rather than new corporate updates [3] - Modular Medical, Inc. (MODD) advanced 5.23% to $0.49, experiencing renewed buying interest despite no new news [4] - Traws Pharma, Inc. (TRAW) rose 2.82% to $1.82 after announcing the filing of a U.S. IND application for its potential oral therapy for influenza, supporting investor optimism around its pipeline [4] - Tiziana Life Sciences Ltd (TLSA) posted a 2.72% gain to $1.51 with no new developments reported [5] - Elutia Inc. (ELUT) climbed 6.64% to $0.90, following a corporate update outlining upcoming milestones for its next-generation antibiotic-eluting biomatrix program [5]

Market Overview - U.S. stocks experienced a decline, with the Nasdaq Composite falling over 350 points, the Dow down 0.55% to 48,922.97, the NASDAQ down 1.58% to 23,335.70, and the S&P 500 down 1.06% to 6,889.76 [1] - Energy shares increased by 2%, while information technology stocks dipped by 1.3% [1] Retail Sales and Economic Indicators - U.S. retail sales rose by 0.6% month-over-month in November, marking the largest increase since July, compared to a revised 0.1% drop in October [2][10] - The U.S. current account deficit decreased by 9.2% to $226.4 billion in Q3, against market expectations of a $238 billion gap [10] - U.S. producer prices increased by 0.2% month-over-month in November, consistent with market expectations [10] Commodity Market - Oil prices rose by 1.3% to $61.97, gold increased by 0.5% to $4,622.10, silver surged by 4.8% to $90.560, and copper rose by 0.3% to $6.0345 [5] European and Asian Markets - European shares were mostly higher, with the eurozone's STOXX 600 up 0.19%, Spain's IBEX 35 up 0.43%, London's FTSE 100 up 0.28%, Germany's DAX down 0.40%, and France's CAC 40 up 0.10% [6] - Asian markets closed mixed, with Japan's Nikkei up 1.48%, Hong Kong's Hang Seng Index up 0.56%, China's Shanghai Composite down 0.31%, and India's BSE Sensex down 0.29% [7] Company-Specific Movements - High Roller Technologies, Inc. shares surged by 289% to $13.64 after announcing a partnership with Crypto.com [9] - Clover Health Investments Corp shares rose by 10% to $2.78 following a year-over-year increase in membership growth [9] - Inspire Veterinary Partners Inc shares increased by 78% to $0.041 after filing to increase its authorized common stock [9] - Briacell Therapeutics Corp shares fell by 53% to $5.09 after pricing a public offering at $5.59 per unit [9] - Plus Therapeutics Inc shares dropped by 39% to $0.29 after announcing a public offering priced at $0.38 per unit [9] - Hub Cyber Security Ltd shares decreased by 39% to $0.33 following a reverse stock split announcement [9]

Core Viewpoint - Plus Therapeutics Inc. announced a public offering priced at $0.38 per unit, aiming to raise approximately $15 million before expenses, which led to a decline in its stock price during trading sessions [1][2]. Group 1: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system [2]. - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [2]. Group 2: Financial and Market Performance - The stock closed at $0.47 on the previous trading day and was down 37.69% at $0.29 during premarket trading on Wednesday [2][7]. - The public offering is expected to close on January 15, 2026, with proceeds designated for working capital and general corporate purposes [2]. - Currently, shares are trading 47.7% below their 20-day simple moving average (SMA) and 48.3% below their 50-day SMA, indicating a bearish trend [5]. Group 3: Technical Indicators - The Relative Strength Index (RSI) stands at 36.82, suggesting neutral momentum, while the MACD is below its signal line, indicating bearish pressure on the stock [6]. - The combination of neutral RSI and bearish MACD suggests mixed momentum [6]. Group 4: Recent Developments - In January, Plus Therapeutics completed a Type B meeting with the U.S. FDA regarding the Reyobiq pivotal trial strategy for leptomeningeal metastases, intending to incorporate FDA feedback into the current dose optimization trial [3]. - In September 2025, CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national agreement with UnitedHealthcare, covering over 51 million people in the U.S. for a laboratory-developed test [4].